Allergan LiRIS Hunner's Lesions

What we are studying

A study to test safety and effectiveness of using lidocaine vs. placebo for patients with IC who have hunner's lesions.

Who is Eligible

  • Genders:
    • Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18+

Eligibility Criteria

  • Diagnosed with interstitial cystitis/bladder pain syndrome
  • Must have Hunner's lesions in the bladder due to IC/BPS
  • If no history of Hunner's lesions subject will not qualify

What is involved

  • 15 clinic visits
  • 10 telephone contacts over a period of about 25 weeks
  • Investigational drug or placebo will be inserted and removed up to 3 times over the course of the study
  • Questionnaires
  • Cystoscopies to insert and remove investigational drug or placebo
  • Physical exams with pelvic
  • Questionnaires
  • Laboratory samples
  • And post void residual ultrasound scans.


You will be compensated per visit completed. Depending on how many treatments received, total compensation varies.

Contact Information

Study Coordinator
Janet Shuping
[email protected]
Principal Investigator
Robert J. Evans, M.D.

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.